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Abstract.  Transforming growth factor-type 13 (TGF-13) 
has been identified as a  constituent of bone matrix 
(Seyedin, S.  M., A.  Y. Thompson, H.  Bentz, D.  M. 
Rosen, J.  M.  McPherson, A.  Conti, N.  R.  Siegel, 
G. R.  Gallupi, and K. A.  Piez,  1986, J.  Biol. Chem. 
261:5693-5695).  We used both developing bone and 
bone-forming cells in vitro to demonstrate the cellular 
origin of this peptide.  TGF-13 mRNA was detected by 
Northern analysis in both developing bone tissue and 
fetal bovine bone-forming cells using human cDNA 
probes.  TGF-13 was shown to be synthesized and 
secreted by metabolically labeled bone cell cultures by 
immunoprecipitation from the medium. Further, TGF-13 
activity was demonstrated in conditioned media from 
these cultures by competitive radioreceptor and growth 
promotion assays. Fetal bovine bone cells (FBBC) 
were found to have relatively few TGF-~ receptors 
(5,800/ce11) with an extremely low Kd of 2.2 pM (high 
binding affinity). In contrast to its inhibitory effects on 
the growth of many cell types including osteosarcoma 
cell lines, TGF-I3 stimulated the growth of subconflu- 
ent cultures of FBBC; it had little effect on the pro- 
duction of collagen by these cells. We conclude that 
bone-forming cells are a  source for the TGF-I~ that is 
found in bone, and that these cells may be modulated 
by this factor in an autocrine fashion. 
T 
RANSFORMING growth factor-type 13  (TGF-13),  ~ dis- 
covered and named for its ability to phenotypically 
transform nonneoplastic fibroblasts in vitro (30),  is 
emerging as the prototype for a  family of multifunctional 
regulatory peptides (38). Many cells, both nonneoplastic and 
neoplastic, synthesize TGF-13 and most of these cells have 
receptors for the peptide. The diverse effects of TGF-[~ on 
cell  function have been further illuminated by the recent 
finding that TGF-[i is similar, if not identical, to cartilage- 
inducing factor-A (36),  a protein isolated from demineral- 
ized bone that induces the formation of cartilage proteogly- 
can and type II collagen from undifferentiated mesenchymal 
cells in vitro (35).  Although platelets are the most concen- 
trated source of TGF-13 in the body (2),  the high yield of 
TGF-I~ from bone (14) (,,ol00-fold greater than from soft tis- 
sues such as placenta [10] and kidney [32]) suggests that bone 
has the greatest total amount of TGF-13. Since the level of 
serum-derived  proteins  in  bone  is  high  (e.g.,  ¢t2  HS- 
glycoprotein, which is synthesized in the liver, can account 
for >2 % of the total bone matrix [40]),  the origin of TGF-13 
found in bone is not entirely clear, and some of it may simply 
be  absorbed  to  the  tissue  from  serum.  Although recent 
studies of the production of growth factors by fetal rat cal- 
varia have demonstrated secretion of TGF-13 into bone organ 
culture medium (5),  this developing tissue contains both 
1. Abbreviations used in thispaper: FBBC, fetal bovine bone cells; TGF-I~, 
transforming growth factor-type 13; NRK, normal rat kidney fibroblasts. 
mineralized and nonmineralized regions, with ceils in non- 
mineralized regions exhibiting distinctly fibroblastic charac- 
teristics (i.e., production of types I and III collagen). Conse- 
quently, the cellular origin of TGF-I~ in this organ culture 
system also is unclear. In the present study, both developing 
bone tissue and bone cell cultures known to exhibit the os- 
teoblastic phenotype were examined at molecular, biosyn- 
thetic, and functional levels. 
Materials and Methods 
Cell Culture 
Primary cultures of FBBC were prepared as previously described (13) by 
incubating collagenase-treated subperiosteal bone fragments in low Ca  ++ 
nutrient medium until the cultures were confluent. Cells were then passaged 
by trypsin-EDTA, and plated at varying densities for the experiments de- 
scribed  below.  Cells were maintained in medium with normal levels of 
Ca  ++ for 48-72 h before the beginning of each experiment. Rat osteosar- 
coma cell lines, ROS 17/2 (22) and UMR 106 (26), were also used for com- 
parison with the nontransformed FBBC. 
Analysis  of TGF-[3 mRNA 
Various developing tissues dissected from fetal rats (day 19) and calves (3-5 
mo of gestation), as well as from the Swarm rat chondrosarcoma were used 
for RNA extraction as previously described (6). RNA was also isolated from 
two rat osteosareoma cell lines (ROS 17/2 and UMR 106), primary cultures 
of FBBC (42), cell cultures derived from bovine skin, tendon, articular car- 
tilage, and smooth muscle, and from human lymphocytes (as a positive con- 
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gels followed by transfer of RNA onto nitrocellulose  (21). Either a nick- 
translated insert (1,060-bp Eco RI fragment)  of a  human TGF-I~ eDNA 
probe (7),  kindly provided  by Dr.  Rik Derynck (Genentech, South San 
Francisco,  CA) or a single stranded (219 bp) subclone of that probe was ra- 
diolabeled and hybridized (Fig.  1 a). The nitrocellulose  blots were washed 
under standard  stringent hybridization conditions (21). 
Biosynthesis of TGF-~ by FBBC 
First passage  FBBC were plated  at a density of 20000 cells/cm  2 and al- 
lowed to recover for 48-72 h. The cells were then incubated with 300 gCi 
of [35S]cysteine for 20 h in DME containing 2 % dialyzed  calf serum and 
10% of the usual concentration of methionine and cysteine. After incuba- 
tion, the medium was saved, the cells were washed several times with PBS, 
and subsequently  extracted with acid-ethanol. The extracts were sonicated, 
centrifuged to remove insoluble debris, and the resulting supernatants were 
used for immunoprecipitation.  Aliquots of media and acid-ethanol extracts, 
containing 5  x  106 TCA-precipitable  counts,  were lyophilized  and resus- 
pended in 400 Ixt of immunoprecipitation  buffer (50 mM Tris-HC1, pH 7.5, 
0.15 M NaC1, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA, 0.005 % methiolate) and boiled for 4 min. The samples were precipi- 
tated three times with normal rabbit serum (20 lxl) and washed Staphylococ- 
cus  aureus (Immunoprecipitin  from  Bethesda  Research  Laboratories, 
Gaithersburg,  MD) (20 Ixl of pelleted S. aureus resuspended in 100 ~tl of 
immunoprecipitation buffer). An IgG fraction of rabbit anti-human TGF-[I 
(34),  prepared by 50% ammonium sulfate precipitation, was added to the 
supernatant from the third preprecipitation,  and the samples incubated over- 
night at 4°C.  In some cases,  the antibody was incubated overnight at 4°C 
with human platelet TGF-~ before being added to the metabolically  labeled 
sample in order to determine the specificity  of the immunoprecipitation. 
The  immunoreactive "I'GF-13 was  recovered  by  incubation with  100  gl 
equivalent S. aureus for 45 rnin at room temperature.  After centrifugation 
the pellet was washed  three times with immunoprecipitation buffer.  The 
washed pellet was boiled for 4 min in a buffer containing 2% SDS and the 
supernatant obtained after centrifugation was subjected  to electrophoresis 
on a  10% polyacrylamide  gel according to Laemmli (17). In some cases, 
samples were boiled in the presence of 5 % 2-mercaptoethanol and subjected 
to electrophoresis  on 12.5% polyacrylamide  gels. The gels were fixed, en- 
hanced with 2,5 diphenyloxazole  dissolved  in DMSO, dried, and exposed 
to Kodak XAR-5  X-ray film at -70°C (4). 
Secretion of TGF-~ by FBBC 
Cells were plated at varying densities and allowed to recover for 48 h. In 
addition, wells containing no cells were set up and incubated identically  for 
the generation of control (no cell) medium to account for the possible re- 
lease of serum during the subsequent incubations.  The cells were then 
washed once with serum-free medium, and incubated in serum-free DME 
containing 50 ~tg/ml ascorbic acid, glutamine,  and penicillin/streptomycin. 
After 48 h, the medium was removed and the cell number determined. The 
conditioned media samples (either  tested directly or after acid activation [18, 
19]) were assayed for TGF-13 activity both by a competitive radioreceptor 
assay (simultaneous  addition of competitor and radiolabeled  TGF-I~) using 
A549 cells (11) and by a bioassay that measures the ability of the peptide 
to induce normal rat kidney fibroblasts (NRK) colony formation in soft agar 
in the presence of epidermal growth factor (31). Human platelet TGF-I~ (2) 
was used as a standard in these assays. In both assays, the original concen- 
Figure 1. Northern blot analy- 
sis of TGF-[3  mRNA from rat 
and  bovine  tissues  and  cul- 
tured cells. (a) A human "IGF-[3 
eDNA  was  radiolabeled  by 
hybridization of synthetic oli- 
gonucleotides complementary 
to the 3' end of the eDNA fol- 
lowed  by  polymer  extension 
using 32p-nucleotides  and DNA 
polymerase, or by electroelu- 
tion of insert eDNA followed 
by nick translation with ¢t-32P- 
dCTP.  Both probes contained 
the sequence encoding for the 
expressed amino acid sequence 
of  TGF-[3.  The  L[3C~ probe 
extends  from  nucleotide  996 
to  nucleotide  2,041  (amino 
acid 53 to beyond the end of 
the  TGF-[3  molecule).  The 
M13  probe begins at nucleo- 
tide 1,736 and ends at nucleo- 
tide  1,955  (aa  229-371).  (b) 
RNA was  isolated from fetal 
rat tissues (calvarial, ephiphy- 
seal,  and  diaphyseal  bone, 
skin, and muscle), the Swarm 
rat chondrosarcoma, and from 
bovine  tissues  (ameloblastic 
layer of developing teeth, cor- 
nea,  liver,  and  brain).  RNA 
from cultures of two rat osteo- 
blastic  cell  lines  (ROS  17/2, 
UMR  106),  primary  FBBC 
taken from fetuses of 3 and 5 
mo,  and fetal bovine tendon, 
skin, and smooth muscle cells were also analyzed.  15 I.tg of total RNA or 3.5 I.tg of poly A + RNA (asterisk)  were subjected to electropho- 
resis in 1.2% agarose gels and transferred to nitrocellulose as described (21). Blots were hybridized with either the ;q3C1 probe (rat tissues 
and cells) or the M13 probe (bovine tissues and cells).  The blots were washed free of unbound probe (1.5  mM sodium citrate,  15 mM 
sodium chloride, 0.1%  SDS at 55°C)  and exposed to X-ray film for 72 h. 
The Journal of Cell Biology, Volume 105, 1987  458 tration was calculated by comparison of a  five or six point dilution (1:2) 
curve of the FBBC-conditioned medium with a standard curve as shown in 
Fig.  3 A. 
Scatchard Analysis of TGF-fl Binding 
Cultures of FBBC as well as ROS 17/2 and UMR 106 rat osteosarcoma cell 
lines were plated at ,',,70-95%  confluency. After 24 h  for recovery, cells 
were preincubated in serum-free medium for 2 h at 37°C to eliminate en- 
dogeneously bound ligand, and used for the determination of receptor num- 
ber/cell and the dissociation constant (Kd) by Scatchard analysis using 12~I- 
labeled human platelet TGF-[I  as previously described (11). 
Biological Effects of TGF-[3 
FBBC were plated at various densities and allowed to recover for 24 h  in 
DME containing 10% FBS, at which time the plating efficiency was deter- 
mined. The cells were washed once with serum-free medium, and subse- 
quently treated with purified human platelet TGF-13 (0-40 pM/ml) in DME 
containing 2% FBS. The effects of TGF-13 on the growth of cells were as- 
sessed after 48 h (FBBC) or after 144 h (ROS 17/2 and UMR 106) by releas- 
ing  100%  of the  cells  (as  determined by  microscopic  evaluation)  with 
trypsin-EDTA, and direct cell count using a  Coulter counter. 
The percentage of collagen synthesized by the cells in the absence and 
presence of TGF-13 (10 and 50 ng/ml) after 18 h of treatment was determined 
by labeling the cells with [3H]proline (20 I.tCi/ml)  for 3 h as described (34) 
and analyzing both the medium and cell layer using the collagenase diges- 
tion method of Peterkofsky (28). 
Results 
Distribution of TGF-B mRNA in Tissues 
and Cultured Cells 
The relative distribution of TGF-[I mRNA in developing rat 
and bovine tissues, and in a variety of cell cultures was inves- 
tigated by Northern analysis of extracted RNA using human 
TGF-[I cDNA probes (Fig. 1 a). In fetal rat tissues, substan- 
tial amounts of hybridization were detected to a message of 
2.4 kb in bone (calvarial, diaphyseal, and ephiphyseal bone), 
muscle, and in the rat Swarm chondrosarcoma. However, rat 
skin tissue contained relatively low levels. The rat osteosar- 
coma-derived cell lines, ROS 17/2 and UMR 106, also con- 
tained TGF-I3 message, the former of which contained the 
highest levels of all the rat samples analyzed (Fig.  1 b). In 
the fetal bovine tissues screened in this study, only the ame- 
loblast layer of the developing tooth, an epithelium whose 
expression is crucial in enamel formation, showed a high de- 
gree of hybridization, while relatively low levels were found 
in cornea, and virtually none in liver and brain. Since extrac- 
tion of mRNA  from even fetal bovine bone is  inefficient, 
mRNA  was prepared from cultures of bone-forming cells 
and compared with cultures of cells derived from other tis- 
sues such as tendon, skin, and smooth muscle. Interestingly, 
all of the bovine cell cultures showed substantial levels of 
TGF-I3 message, and in contrast to the rat tissue, bovine skin 
fibroblasts contained relatively more TGF-I3 mRNA than the 
other cultures. In some, but not all experiments, the migra- 
tion of TGF-I3 mRNA of smooth muscle cells was slightly 
faster than that of authentic TGF-13  mRNA derived from hu- 
man lymphocytes (Fig.  1 b). 
Expression of TG  F-~ 
Immunoprecipitation  of  [35S]cysteine-labeled  media  from 
FBBC with a polyclonal antibody to TGF-I3 revealed a poly- 
peptide of Mr 25,000 that was converted to a polypeptide of 
Mr  12,500  after reduction of disulfide bonds,  identical to 
Figure 2. Immunoprecipitation of FBBC extracts and media. Cells 
were labeled for 20 h with [35S]cysteine  and media or acid-ethanol 
cell extracts were immunoprecipitated with either anti-'rGF-I~ (IP), 
or with antibody preincubated with unlabeled TGF-13  (IP+TGF-I~). 
Nonreduced samples (-ME) were subjected to electrophoresis on 
10% polyacrylamide gels while reduced samples (+ME) were sub- 
jected to electrophoresis on 12.5% polyacrylamide gels. In each 
case, t25I-labeled  human platelet TGF-13, along with standard mo- 
lecular weight markers (the migration of which are indicated on the 
far left and far right of the figure) were subjected to electrophoresis 
on the same gels for comparison. 
the behavior of L~5I-labeled  human platelet TGF-13 (Fig. 2). 
The immunoprecipitation of these polypeptides was blocked by 
the pretreatment of the antibody with pure, unlabeled TGF-13. 
Interestingly, relatively little TGF-I3 was identified in the cell 
layer fractions, suggesting that the peptide is secreted from, 
but not bound in the cell layer at the density used in this ex- 
periment, or in the absence of mineralization. A long radio- 
labeling time (20 h) was used in this experiment to assure 
that  sufficient  radiolabeled  TGF-I3  accumulated  in  the 
medium  to be  detected by  immunoprecipitation.  The ex- 
perimental design reduced the probability that a significant 
amount of TGF-I3 would be detected in the cell layer. How- 
ever, studies with Ha-ras-transfected NIH-3T3 cells radiola- 
beled under a  variety of conditions indicate that TGF-I3 is 
rapidly secreted from the cells making the intracellular TGF-I3 
content below the detection limit (Flanders, K. C., unpub- 
lished results).  Further,  [3sS]cysteine-labeled TGF-13 could 
only be precipitated from the medium (that was not acid acti- 
vated)  after boiling  the  sample,  while  12SI-labeled human 
platelet TGF-I~ (which was previously acid activated) can be 
precipitated without boiling. This observation indicates that 
boiling either unmasks epitopes recognized by the antibody, 
or is equivalent to acid activation in the conversion of latent 
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Figure 3.  Secretion of biologically  active TGF-I~ by FBBC. (A) 
Medium conditioned by 1.8  x  105 FBBC was acidified to pH 2, 
neutralized, and assayed in a competitive radioreceptor binding as- 
say using A549 cells and human platelet TGF-I~  as a standard (11). 
(B) The concentration of TGF-13 in 48-h medium conditioned by 
FBBC cells at varying densities was determined in the binding assay 
and plotted versus the log of  the cell number. Monolayer confluency 
was reached at a log cell number of 5.7. Control (no cell) medium 
and unconditioned medium had no assayable I"GF-13. Data repre- 
sents the average of duplicate determinations for one of two repre- 
sentative experiments. 
TGF-13 to  the  active  form (Flanders,  K.  C.,  unpublished 
results). 
The biological activity of the TGF-13 in the conditioned 
medium of FBBC was assayed both by competitive radio- 
receptor binding  (Fig.  3)  and by stimulation of NRK cell 
colony formation in soft agar in the presence of epidermal 
growth factor (not shown). The concentration of TGF-I~ pres- 
ent  in  the  acid-activated  conditioned  medium of cultures 
ranging in density from 900 to 61,000  cells/cm  2 was deter- 
mined in a competitive radioreceptor assay using A549 cells 
and a human platelet TGF-13 standard (Fig. 3 A). The amount 
of TGF-13 in the medium increased with increasing cell num- 
ber, although the rate of secretion remained constant at ,,o14 
fmol/106  cells/h;  the  concentration  of TGF-13 in  the  48-h 
medium conditions by 0.84  ×  106 cells was ~380  5:80 pM 
compared with 35  4- 5 pM for 0.08  x  106 cells (Fig. 3 B). 
These results  were verified by an assay using the FBBC- 
conditioned medium to induce NRK cell colony formation 
in soft agar (data not shown), thus ruling out any possibility 
of artifactual interference by a putative binding protein in the 
radioreceptor assay.  Acid  activation of FBBC-conditioned 
medium was necessary to determine the total amount of the 
TGF-O, confirming the latent nature of TGF-I3 secreted by 
FBBC. However, up to 25 % of the TGF-13 secreted was active 
without acid activation in this assay (data not shown), sug- 
gesting that latent TGF-13 may serve as a more stable pool 
that is activated by the cells as needed. 
Characterization of TGF-~ Receptor Binding 
The binding of 125I-labeled human platelet TGF-13 to recep- 
tors on FBBC was compared with that on the rat osteosar- 
coma cell lines (ROS 17/2 and UMR 106) by Scatchard anal- 
ysis (Fig. 4). All three cell types had relatively few receptors 
per cell (2,200 4- 550 for ROS, 7,100:1:3,300 for UMR, and 
5,600  +  160 for FBBC) with very low Ko values of 3.0  + 
0.4, 7.8  4-  1.9, and 2.0  4- 0.2 pM, respectively. Analysis of 
the binding of TGF-13 to the FBBC, but not the cloned os- 
teosarcoma cell lines,  suggested the existence of a  second 
class of receptors of a higher abundance (10,000/cell)  and rel- 
atively higher Ka of 12 pM. 
Modulation of Osteoblast Activity in TGF-[3 
The addition of low levels (<40 pM) of human platelet TGF-~ 
to FBBC plated at varying densities stimulated cell growth 
(Fig. 5 A). Two days after addition, 24-40 pM TGF-I~ caused 
a twofold increase in the number of cells plated at low density 
(10,000 cells/cm2). Interestingly, at both sparse and high cell 
densities,  TGF-13 had little mitogenic effect. The growth of 
both ROS  17/2 (Fig.  5 B) and UMR  106  (not shown)  os- 
teosarcoma cells  at all densities  studied  was  inhibited  by 
TGF-13 at the same concentrations that stimulated growth of 
first passage FBBC  cells.  Again,  the inhibitory effect was 
less pronounced when the cells were plated at higher den- 
sities. 
Since TGF-13 has been shown to significantly increase syn- 
thesis of collagen and fibronectin by fibroblastic cells,  its 
ability to modulate synthesis of matrix proteins by FBBC was 
also  examined.  TGF-I~  (10  and  50  ng/ml)  had  an  overall 
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Figure  4. Scatchard analysis of TGF-13 
binding to ROS 17/2 (a), UMR 106 
(b), and FBBC (c). Cells were plated 
at  ~o75-90% contluency  in  35-mm 
dishes, washed, and incubated at 37°C 
for 2 h in serum-free medium to re- 
move all bound ligands, and then in- 
cubated  with  increasing  concentra- 
tions  of t25I-labeled human  platelet 
TGF-I~ for 2 h at room temperature. 
Total cell-associated radioactivity and 
free TGF-I~ concentration  were de- 
termined  as  previously  described 
(11); data  were  corrected  for  non- 
specific binding  in the  presence  of 
10 nM  TGF-I~. The data shown are 
from a representative determination; 
the experiments were repeated three 
additional  times  for each cell  type 
with similar results. 
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Figure 5.  Effects of TGF-13 on growth  of 
FBBC (solid symbols) and ROS 17/2 (open 
symbols).  FBBC were plated at four differ- 
ent densities and allowed to recover in DME 
containing 10% FCS. After 24 h, the ceils 
were washed once with serum-free DME, 
and  subsequently  treated  for  48  h  with 
DME  containing  2%  FCS  with  12  (e, 
o), 24  (A,  zx), or 40 pM (n,  D) purified 
human platelet TGF-13. Cell number was de- 
termined  by direct  cell  count  of trypsin- 
EDTA released cells. ROS 17/2 cells were 
treated in a similar fashion except that after 
plating at similar densities,  the cells were 
washed after 6 h of recovery and treated for 
144  h  with  the  same levels of TGF-13 in 
DME containing 2% plasma-derived  serum.  The data shown are from one of two similar experiments. Each point is the mean of three 
different samples, and the cell counts from each sample were all within 10% of the mean. Of the cells plated at 1.0 ×  104 cells/cm 2, FBBC 
were mitogenically stimulated (28  +  1 x  103 cells in control wells and 54  +  5  ×  103 cells in wells treated with 24 pM of TGF-13), 
whereas ROS cells were inhibited (51  +  2  ×  103 cells in control wells and 21  +  1 ×  103 cells in wells treated with 12 pM TGF-13). 
However, there was no effect on the percentage of bacterial 
collagenase-sensitive protein  secreted by the cells,  which 
was found to be 50% in control, and 45 and 47% in cultures 
treated with  10 and 50 ng/ml, respectively. Analysis of the 
cell  layers  fractions  were  similar.  In contrast,  TGF-I3  in- 
creased relative collagen secretion in ROS 17/2 cells from 1.4 
(control) to 3.8 % (50 ng/ml TGF-13 treatment). While this is 
a threefold increase, it should be noted that the overall per- 
centage of collagen secreted by these cells was substantially 
less than that of FBBC (1.4 as compared with 50%). 
Discussion 
The recently  established  identity of TGF-[~ and  cartilage- 
inducing factor A  (36) and the recently reported immuno- 
localization of TGF-~ to bone (8), indicates that bone is per- 
haps the most abundant source of'l'GF-[3 in the body (14, 35), 
with a concentration ,~100-fold greater than that in soft tis- 
sues such as placenta (10) or kidney (32). We show here that 
one of the sources of TGF-[I in bone is the bone-forming cells 
themselves. These cells were found to (a) transcribe TGF-[i 
mRNA; (b) synthesize and secrete this peptide; (c) bear high 
affinity  cell  surface  receptors,  and  (d)  be  mitogenically 
stimulated by TGF-[3. The amount of TGF-[3 secreted by the 
confluent FBBC is ~sixfold higher than from virally trans- 
formed cells and between 10- and 20-fold higher than from 
nontransformed cells (1). Although the TGF-[~ secreted by 
FBBC in vitro is predominantly in a  latent form that must 
be activated before it can be recognized by antibodies or can 
bind to its receptor, up to 25 % is in the active form. The im- 
plications of this for a potential autocrine action of TGF-[3 
on FBBC are not presently understood. 
The dissociation constants (Kd) for binding of TGF-[~ to 
receptors on either FBBC or the rat osteosarcoma cell lines, 
ROS 17/2 and UMR 106, are very low (2-6 pM), indicating 
the presence of very high affinity-binding sites on these cells. 
Scatchard analyses of the binding of TGF-[I to 33 different 
cell lines has shown that cells of mesenchymal origin have 
7,000-80,000 receptors/cell with dissociation constants rang- 
ing from 13 to 60 pM (41a); these osteoblastic cells are thus 
distinguished by their low receptor number and high binding 
affinity. A second, more abundant, class of receptors with a 
relatively lower affinity was also identified (Fig. 4 c). These 
receptors are not of the very low affinity class (Kd of 4 nm) 
previously described (11), but are similar to those found in 
bovine  skin  fibroblasts derived  from fetuses  of the  same 
gestational age (Roberts, A. B., and P.  Gehron Robey, un- 
published results). Thus, they may be indicative of either the 
presence of undifferentiated osteoblasts or fibroblasts pres- 
ent in small numbers in the culture.  Alternatively, this sec- 
ond class of receptors may account for the binding of TGF-I~ 
to a receptor for a closely related molecule, cartilage-induc- 
ing factor-B (35) with a relatively lower affinity for TGF-13. 
In this system, TGF-13 appears to promote the growth of 
the same cells that produce it.  Moreover, the finding that 
~25 % of the secreted TGF-13 is in an active form suggests 
that it might potentially function as an autocrine growth fac- 
tor for these cells. However, it is possible that the mitogenic 
effect of TGF-13 may be the consequence of the induction of 
other growth factors by the cells as has been shown in the 
AKR-2B cell line (37, 20). The stimulation of the anchorage- 
dependent growth of FBBC by TGF-[3 is in striking contrast, 
however, to its inhibition of anchorage-dependent growth of 
the two osteosarcoma cell lines studied here, as well as that 
of many  other  cell  types  including  a  clonal  murine  cal- 
varia-derived cell line, MC3T3E1 (25), fibroblasts (33,  41), 
epithelial cells (23,  33), myoblasts (9), hepatocytes (15, 24), 
and endothelial cells (3); before this, only primary human 
mesothelial cells have been reported to be stimulated to grow 
in monolayer culture by TGF-[~ (12). The density-dependent 
effects of TGF-I3 on stimulation of growth of FBBC are analo- 
gous to those seen on inhibition of growth of either fibro- 
blasts (32) or the osteosarcoma cells (Fig. 5 B) by this peptide 
(i.e., the growth of subconfluent cultures of ROS  17/2 cells 
or of NRK fibroblasts is inhibited by TGF-13, but the effect 
is diminished as the cells approach confluency). 
The different biological response patterns to TGF-13 of the 
two rat osteosarcoma cell lines compared with FBBC em- 
phasize that the osteosarcoma cell lines may not exhibit all 
of the characteristics of the osteoblastic phenotype as had 
been previously suggested, based on their response to para- 
thyroid hormone (22, 27).  Thus, identical concentrations of 
TGF-13 inhibit the growth of the osteosarcoma cell lines and 
stimulate the growth of FBBC. Moreover, ROS 17/2 cells but 
Gehron Robey et al. Bone Cells Synthesize TGF-[3  461 not FBBC, respond to TGF-13 with a selective increase in col- 
lagen synthesis compared with that of noncollagenous pro- 
teins.  Significant differences were found,  however,  in the 
protein  synthetic  pattern  of these two cell types  (collagen 
secretion relative to total secreted proteins was 1.4 and 50% 
for ROS  17/2 and FBBC,  respectively).  Also in contrast  to 
FBBC, fibroblastic cells are stimulated to increase collagen 
synthesis by TGF-13 (16, 34). These data taken together suggest 
that TGF-I~ may serve as a mitogen for FBBC to expand this 
population of cells rather than to induce them to elaborate 
more matrix (i.e., become more differentiated).  Expansion 
of this population of cells would also result in the elaboration 
of more TGF-13 which could, in turn, act on other target cells. 
However, it should be noted that the effect of TGF-13 on colla- 
gen production by FBBC cells may be density dependent, 
and further  studies  are  needed  to determine  the  effect of 
TGF-13 on protein synthesis in superconfluent FBBC when 
matrix production and mineralization are initiated. 
The abundance of TGF-13 in bone (14, 35), the high affinity 
receptor binding, and the stimulation of the growth of FBBC, 
taken together with the finding that TGF-13 can induce secre- 
tion of collagen and cartilage proteoglycans in mesenchymal 
cells  (16, 34,  35)  suggest  a unique  role for TGF-13 in the 
growth and remodeling processes of hard tissues. Moreover, 
the findings  that TGF-I~ stimulates bone resorption (39) and 
is itself released by organ  cultures of developing bone ex- 
posed to parathyroid hormone (29) suggest that TGF-13 may 
be involved in the "coupling" of bone resorption and bone 
formation to maintain  normal rates of bone turnover  (29). 
Further  studies may clarify its role in bone metabolism in 
normal and diseased states. 
The authors thank Lalage Wakefield for helpful suggestions on the Scatchard 
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